Advances in targeted therapy for metastatic non-squamous NSCLC have now expanded from EGFR and ALK to additional oncogenic targets, including ROS1, BRAF, RET, HER2, NTRK, and MET. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.